Study of NEO-811 for advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced clear cell kidney cancer that has spread and can't be removed with surgery.
- You have tried standard treatments or are unable to take them.
- You are well enough to be up and about (ECOG score 0 or 1).
- You have a tumor sample (from a past biopsy or surgery) that can be tested.
- Your blood counts and kidney/liver function meet minimum levels (hemoglobin ≥10, ANC ≥1000, platelets ≥100,000, and eGFR ≥60).
- You can swallow pills and your body can absorb the medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This study tests a new medicine called AK112 for people with advanced kidney cancer (clear cell type) that has not yet been treated. The goal is to see if this medicine can help shrink or slow the cancer, and to check its safety.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.